hrp0098rfc14.4 | Fetal and Neonatal Endocrinology | ESPE2024

Neurodevelopmental response to nifedipine treatment in an infant with Congenital Hyperinsulinism due to de novo gain-of-function CACNA1D variant.

Pujari Divya , Conlon Alison , Wakeling Emma , Houghton Jayne , Flanagan Sarah , Eldred Carey , Starling Luke , Kaliakatsos Marios , Dastamani Antonia

Introduction: Congenital hyperinsulinism (CHI) is a rare condition often caused by variants in genes that regulate insulin production. Among the 30 genes identified, CACNA1D, which encodes L-type calcium channels in various cells, is a rare cause. Variants in CACNA1D lead to a multisystem disorder characterized by developmental delay, intellectual disability, autism, hypotonia, seizures, primary aldosteronism, CHI, hearing loss, visual issues...